Supernus Patent-Cliff Exposure & CMS Drug Spending Portfolio
Supernus (US): 4 reconciled FDA prescription therapies (31.7% 2025 to 2030 cliff risk), $426.6M 2024 CMS Part D & Medicaid spend, and 30 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 4 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 31.7% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $426.6M |
| 2024 Medicare Part D Spend | $153.0M |
| 2024 Medicaid Spend | $273.6M |
| California HCAI SB 17 Filings | 30 WAC filings (max 19.2% 2-yr change) |